Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 141 of the 141 references it cites were found in a registry or an index.
Abstract
Table 1dProperties of currently available glucose-lowering agents that may guide treatment choice in individual patients with type 2 diabetes mellitus Class Compound(s) Cellular mechanism
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Antihyperglycemic therapy in type 2 diabetes: general recommendations. Moving from the top to the bottom of the figure, potential sequences of antihyperglycemic therapy. In most patients, begin with lifestyle changes; metformin monotherapy is added at, or soon after, diagnosis (unless there are explicit contraindications). If the HbA1c target is not achieved after ∼3 months, consider one of the five treatment options combined with metformin: a sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, or basal insulin. (The order in the chart is determined by historical introduction and route of administration and is not meant to denote any specific preference.) Choice is based on patient and drug characteristics, with the over-riding goal of improving glycemic control while minimizing side effects. Shared decision making with the patient may help in the selection of therapeutic options. The figure displays drugs commonly used both in the U.S. and/or Europe. Rapid-acting secretagogues (meglitinides) may be used in place of sulfonylureas. Other drugs not shown (α-glucosidase inhibitors, colesevelam, dopamine agonists, pramlintide) may be used where available in selected patients but have modest efficacy and/or limiting side effects. In patients intolerant of, or with contraindications for, metformin, select initial drug from other classes depicted and proceed accordingly. In this circumstance, while published trials are generally lacking, it is reasonable to consider three-drug combinations other than metformin. Insulin is likely to be more effective than most other agents as a third-line therapy, especially when HbA1c is very high (e.g., ≥9.0%). The therapeutic regimen should include some basal insulin before moving to more complex insulin strategies (Fig. 3). Dashed arrow line on the left-hand side of the figure denotes the option of a more rapid progression from a two-drug combination directly to multiple daily insulin doses, in those patients with severe hyperglycemia (e.g., HbA1c ≥10.0–12.0%). DPP-4-i, DPP-4 inhibitor; Fx's, bone fractures; GI, gastrointestinal; GLP-1-RA, GLP-1 receptor agonist; HF, heart failure; SU, sulfonylurea. aConsider beginning at this stage in patients with very high HbA1c (e.g., ≥9%). bConsider rapid-acting, nonsulfonylurea secretagogues (meglitinides) in patients with irregular meal schedules or who develop late postprandial hypoglycemia on sulfonylureas. cSee Table 1 for additional potential adverse effects and risks, under “Disadvantages.” dUsually a basal insulin (NPH, glargine, detemir) in combination with noninsulin agents. eCertain noninsulin agents may be continued with insulin (see text). Refer to Fig. 3 for details on regimens. Consider beginning at this stage if patient presents with severe hyperglycemia (≥16.7–19.4 mmol/L [≥300–350 mg/dL]; HbA1c ≥10.0–12.0%) with or without catabolic features (weight loss, ketosis, etc.).](https://figures.cochat.ai/paper-figures/128f54a8a50241f9bf5b53c4e153f5da/management-of-hyperglycemia-in-type-2-diabetes-a-patient-centered-approach-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prolonged follow up showed that in some instances the benefit is retained for 10 years or more153–155”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [154]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For patients with type 2 diabetes, the risk of hypoglycemia depends on the medications used (96).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For patients with type 2 diabetes, sulfonylureas are the oral agents that pose the greatest risk for iatrogenic hypoglycemia and substitution with other classes of oral agents or even glucagon-like peptide 1 analogs should be considered in the event of troublesome hypoglycemia (96).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [96]
The cited source says what the claim attributes to it.
In the citing paper
“For patients with type 2 diabetes, sulfonylureas are the oral agents that pose the greatest risk for iatrogenic hypoglycemia and substitution with other classes of oral agents or even glucagon-like peptide 1 analogs should be considered in the event of troublesome hypoglycemia (96).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [96]
The cited source says what the claim attributes to it.
In the citing paper
“For patients with type 2 diabetes, the risk of hypoglycemia depends on the medications used (96).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [96]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“Relationship of glycemic control to outcomes It is well established that the risk of microvascular and macrovascular complications is related to glycemia, as measured by HbA1c; this remains a major focus of therapy (29).”
BackgroundThe metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Research works printed but not linked: 3
- Berard, 2008, Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada, Canadian Journal of Diabetes, 32, S1
- NICE, 2009, Type 2 Diabetes: The Management of Type 2 Diabetes: NICE Clinical Guideline 87
- Committee on Quality of Health Care in America, 2001, Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century
Cited by
Items 101–200 of 255
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s007 · Cited by 263
Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Buse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W. (2014) · Diabetes Care · doi:10.2337/dc14-0785 · Cited by 259
Self-citationDedov, I. I., Shestakova, M. V., Mayorov, A. Y., Vikulova, O. K., Galstyan, G. R., Kuraeva, T. L., Peterkova, V. A., Smirnova, O. M., Starostina, E. G., Surkova, E. V., et al. (2019) · Diabetes mellitus · doi:10.14341/dm221s1 · Cited by 257
Kramer, C. K., Zinman, B., & Retnakaran, R. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70006-8 · Cited by 257
Quality of Care of People With Type 2 Diabetes in Eight European Countries
Stone, M. A., Charpentier, G., Doggen, K., Kuss, O., Lindblad, U., Kellner, C., Nolan, J., Pazderska, A., Rutten, G., Trento, M., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1759 · Cited by 257
Reframing chronic pain as a disease, not a symptom: rationale and implications for pain management
Clauw, D. J., Essex, M. N., Pitman, V., & Jones, K. D. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1574403 · Cited by 256
Forst, T., Guthrie, R., Goldenberg, R., Yee, J., Vijapurkar, U., Meininger, G., & Stein, P. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12273 · Cited by 255
Li, L., Shen, J., Bala, M. M., Busse, J. W., Ebrahim, S., Vandvik, P. O., Rios, L. P., Malaga, G., Wong, E., Sohani, Z., et al. (2014) · BMJ · doi:10.1136/bmj.g2366 · Cited by 254
Nathan, D. M., Buse, J. B., Kahn, S. E., Krause-Steinrauf, H., Larkin, M. E., Staten, M., Wexler, D., Lachin, J. M., & the GRADE Study Research Group (2013) · Diabetes Care · doi:10.2337/dc13-0356 · Cited by 254
Self-citationSha, S., Polidori, D., Heise, T., Natarajan, J., Farrell, K., Wang, S. ‐., Sica, D., Rothenberg, P., & Plum‐Mörschel, L. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12322 · Cited by 249
Yoga for Adults with Type 2 Diabetes: A Systematic Review of Controlled Trials
Innes, K. E., & Selfe, T. K. (2016) · Journal of Diabetes Research · doi:10.1155/2016/6979370 · Cited by 248
Johansen, M. Y., MacDonald, C. S., Hansen, K. B., Karstoft, K., Christensen, R., Pedersen, M., Hansen, L. S., Zacho, M., Wedell-Neergaard, A.-S., Nielsen, S. T., et al. (2017) · JAMA · doi:10.1001/jama.2017.10169 · Cited by 244
Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Ways, K., Desai, M., Shaw, W., Capuano, G., Alba, M., et al. (2015) · Diabetes Care · doi:10.2337/dc14-1237 · Cited by 233
Self-citationAchievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014
Carls, G., Huynh, J., Tuttle, E., Yee, J., & Edelman, S. V. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0280-5 · Cited by 228
“patient-centered approach to diabetes management and were introduced in 2012 [3].”
BackgroundMethodInfluentialOdgers‐Jewell, K., Ball, L. E., Kelly, J. T., Isenring, E. A., Reidlinger, D. P., & Thomas, R. (2017) · Diabetic Medicine · doi:10.1111/dme.13340 · Cited by 224
Saslow, L. R., Kim, S., Daubenmier, J. J., Moskowitz, J. T., Phinney, S. D., Goldman, V., Murphy, E. J., Cox, R. M., Moran, P., & Hecht, F. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091027 · Cited by 221
“The MCCR diet classes were taught by a registered dietician with several years of diabetes education experience (author RC), using information from the American Diabetes Association Complete Guide to Diabetes [9], supplemented by several additional resources [4,10].”
MethodMarx, N., Rosenstock, J., Kahn, S. E., Zinman, B., Kastelein, J. J., Lachin, J. M., Espeland, M. A., Bluhmki, E., Mattheus, M., Ryckaert, B., et al. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115570301 · Cited by 212
Coronary Artery Disease and Diabetes Mellitus
Aronson, D., & Edelman, E. R. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2014.04.001 · Cited by 222
Abdul‐Ghani, M. A., Puckett, C., Triplitt, C., Maggs, D., Adams, J., Cersosimo, E., & DeFronzo, R. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12417 · Cited by 208
Briggs Early, K., & Stanley, K. (2018) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2017.11.021 · Cited by 203
A multicenter observational study of incretin-based drugs and heart failure
Filion, K. B., Azoulay, L., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Hu, N., Paterson, J. M., Targownik, L., Turin, T. C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506115 · Cited by 196
Umapathysivam, M. M., Lee, M. Y., Jones, K. L., Annink, C. E., Cousins, C. E., Trahair, L. G., Rayner, C. K., Chapman, M. J., Nauck, M. A., Horowitz, M., et al. (2014) · Diabetes · doi:10.2337/db13-0893 · Cited by 193
Self-citationWayne, N., Perez, D. F., Kaplan, D. M., & Ritvo, P. (2015) · Journal of Medical Internet Research · doi:10.2196/jmir.4871 · Cited by 192
2022 National standards for diabetes self-management education and support
Davis, J., Fischl, A. H., Beck, J., Browning, L., Carter, A., Condon, J. E., Dennison, M., Francis, T., Hughes, P. J., Jaime, S., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2396 · Cited by 191
An Effective Model of Diabetes Care and Education: Revising the AADE7 Self-Care Behaviors ®
American Association of Diabetes Educators (2020) · The Diabetes Educator · doi:10.1177/0145721719894903 · Cited by 184
Cai, X., Yang, W., Gao, X., Chen, Y., Zhou, L., Zhang, S., Han, X., & Ji, L. (2018) · Obesity · doi:10.1002/oby.22066 · Cited by 181
Cefalu, W. T., Leiter, L. A., de Bruin, T. W. A., Gause-Nilsson, I., Sugg, J., & Parikh, S. J. (2015) · Diabetes Care · doi:10.2337/dc14-0315 · Cited by 182
Mabilleau, G., Mieczkowska, A., & Chappard, D. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12102 · Cited by 178
“8 kg on average in the present study), whereas it is neutral in patients on DPP-4 inhibitors.(20,21) Weight loss after the age of 50 years as been associated previously with an increased risk of fracture in overweight and obese individuals.”
Background2022 National standards for diabetes self-management education and support
Davis, J., Fischl, A. H., Beck, J., Browning, L., Carter, A., Condon, J. E., Dennison, M., Francis, T., Hughes, P. J., Jaime, S., et al. (2022) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106211072203 · Cited by 169
Fortmann, A. L., Gallo, L. C., Garcia, M. I., Taleb, M., Euyoque, J. A., Clark, T., Skidmore, J., Ruiz, M., Dharkar-Surber, S., Schultz, J., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0230 · Cited by 169
Gummesson, A., Nyman, E., Knutsson, M., & Karpefors, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12971 · Cited by 162
“weight loss in the patients who are overweight or obese.(6) Unfortunately, weight management by non-surgical means can be very challenging and even intensive lifestyle interventions have been unable to produce substantial, long-term weight loss in patients with T2D.”
BackgroundNew mechanisms of metformin action: Focusing on mitochondria and the gut
Hur, K. Y., & Lee, M. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12328 · Cited by 161
Sussman, J. B., Kerr, E. A., Saini, S. D., Holleman, R. G., Klamerus, M. L., Min, L. C., Vijan, S., & Hofer, T. P. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.5110 · Cited by 160
Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158
Lexis, C. P. H., van der Horst, I. C. C., Lipsic, E., Wieringa, W. G., de Boer, R. A., van den Heuvel, A. F. M., van der Werf, H. W., Schurer, R. A. J., Pundziute, G., Tan, E. S., et al. (2014) · JAMA · doi:10.1001/jama.2014.3315 · Cited by 158
Sussman, J. B., Kent, D. M., Nelson, J. P., & Hayward, R. A. (2015) · BMJ · doi:10.1136/bmj.h454 · Cited by 143
Abd El Aziz, M. S., Kahle, M., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12804 · Cited by 155
Self-citationEvidence-based practice guideline for the treatment for diabetes in Japan 2013
Tajima, N., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Fujimoto, K., Sakamoto, M., & Haneda, M. (2015) · Diabetology International · doi:10.1007/s13340-015-0206-2 · Cited by 154
Carls, G. S., Tuttle, E., Tan, R.-D., Huynh, J., Yee, J., Edelman, S. V., & Polonsky, W. H. (2017) · Diabetes Care · doi:10.2337/dc16-2725 · Cited by 153
Hsu, W. C., Lau, K. H. K., Huang, R., Ghiloni, S., Le, H., Gilroy, S., Abrahamson, M., & Moore, J. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0160 · Cited by 135
Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release
Garvey, W. T., Ryan, D. H., Bohannon, N. J. V., Kushner, R. F., Rueger, M., Dvorak, R. V., & Troupin, B. (2014) · Diabetes Care · doi:10.2337/dc14-0930 · Cited by 149
Understanding patient portal use: implications for medication management
Osborn, C. Y., Mayberry, L. S., Wallston, K. A., Johnson, K. B., & Elasy, T. A. (2013) · Journal of Medical Internet Research · doi:10.2196/jmir.2589 · Cited by 147
Shi, Q., Liu, S., Fonseca, V. A., Thethi, T. K., & Shi, L. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024954 · Cited by 144
Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management
Scaroni, C., Zilio, M., Foti, M., & Boscaro, M. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1105 · Cited by 140
Faillie, J.-L., Yu, O. H., Yin, H., Hillaire-Buys, D., Barkun, A., & Azoulay, L. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1531 · Cited by 134
Brunton, S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12361 · Cited by 130
Rosenstock, J., Hanefeld, M., Shamanna, P., Min, K. W., Boka, G., Miossec, P., Zhou, T., Muehlen-Bartmer, I., & Ratner, R. E. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.01.012 · Cited by 130
Torbjørnsen, A., Jenum, A. K., Småstuen, M. C., Årsand, E., Holmen, H., Wahl, A. K., & Ribu, L. (2014) · JMIR mHealth and uHealth · doi:10.2196/mhealth.3535 · Cited by 117
Mancia, G., Cannon, C. P., Tikkanen, I., Zeller, C., Ley, L., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07703 · Cited by 128
Shields, B. M., Peters, J. L., Cooper, C., Lowe, J., Knight, B. A., Powell, R. J., Jones, A., Hyde, C. J., & Hattersley, A. T. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009088 · Cited by 126
Personalized type 2 diabetes management: an update on recent advances and recommendations
Williams, D. M., Jones, H., & Stephens, J. W. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s331654 · Cited by 121
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Juurlink, D. N., Targownik, L. E., Turin, T. C., et al. (2016) · BMJ · doi:10.1136/bmj.i581 · Cited by 120
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Hu, N., Juurlink, D. N., Paterson, J. M., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1522 · Cited by 120
SIRT1, p66Shc, and Set7/9 in Vascular Hyperglycemic Memory
Paneni, F., Volpe, M., Lüscher, T. F., & Cosentino, F. (2013) · Diabetes · doi:10.2337/db12-1648 · Cited by 118
Do sulphonylureas still have a place in clinical practice?
Khunti, K., Chatterjee, S., Gerstein, H. C., Zoungas, S., & Davies, M. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30025-1 · Cited by 116
Kim, K. H., Jeong, Y. T., Kim, S. H., Jung, H. S., Park, K. S., Lee, H.-Y., & Lee, M.-S. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.09.026 · Cited by 112
Probiotics for the management of type 2 diabetes mellitus: A systematic review and meta-analysis
Samah, S., Ramasamy, K., Lim, S. M., & Neoh, C. F. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.06.014 · Cited by 112
Fear of hypoglycemia---an underestimated problem
Przezak, A., Bielka, W., & Molęda, P. (2022) · Brain and Behavior · doi:10.1002/brb3.2633 · Cited by 110
Mulvihill, E. E., Varin, E. M., Gladanac, B., Campbell, J. E., Ussher, J. R., Baggio, L. L., Yusta, B., Ayala, J., Burmeister, M. A., Matthews, D., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.007 · Cited by 102
Self-citationDiabetes self-management programmes in older adults: A systematic review and meta-analysis
Sherifali, D., Bai, J. ‐., Kenny, M., Warren, R., & Ali, M. U. (2015) · Diabetic Medicine · doi:10.1111/dme.12780 · Cited by 102
Buysman, E. K., Liu, F., Hammer, M., & Langer, J. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0199-z · Cited by 101
Lee, S., Zhou, J., Wong, W. T., Liu, T., Wu, W. K. K., Wong, I. C. K., Zhang, Q., & Tse, G. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00751-4 · Cited by 97
Seidu, S., Kunutsor, S. K., Topsever, P., Hambling, C. E., Cos, F. X., & Khunti, K. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13724 · Cited by 97
Lopez, J., Annunziata, K., Bailey, R., Morisky, D. E., & Rupnow, M. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s58813 · Cited by 96
Selvin, E. (2016) · Diabetes Care · doi:10.2337/dc16-0042 · Cited by 96
Mediterranean diet and type 2 diabetes
Esposito, K., & Giugliano, D. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2516 · Cited by 96
McGill, M., Blonde, L., Chan, J. C. N., Khunti, K., Lavalle, F. J., & Bailey, C. J. (2017) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.12.001 · Cited by 95
Sebire, S. J., Toumpakari, Z., Turner, K. M., Cooper, A. R., Page, A. S., Malpass, A., & Andrews, R. C. (2018) · BMC Public Health · doi:10.1186/s12889-018-5114-5 · Cited by 94
Metformin and Cancer: Mounting Evidence Against an Association
Suissa, S., & Azoulay, L. (2014) · Diabetes Care · doi:10.2337/dc14-0500 · Cited by 93
Rodbard, H. W., Visco, V. E., Andersen, H., Hiort, L. C., & Shu, D. H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70090-1 · Cited by 91
Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk
Naude, C. E., Brand, A., Schoonees, A., Nguyen, K. A., Chaplin, M., & Volmink, J. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013334.pub2 · Cited by 91
Emerging treatments for post-transplantation diabetes mellitus
Jenssen, T., & Hartmann, A. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.59 · Cited by 90
Bowen, M. E., Cavanaugh, K. L., Wolff, K., Davis, D., Gregory, R. P., Shintani, A., Eden, S., Wallston, K., Elasy, T., & Rothman, R. L. (2016) · Patient Education and Counseling · doi:10.1016/j.pec.2016.03.017 · Cited by 89
Hope, S. V., Wienand-Barnett, S., Shepherd, M., King, S. M., Fox, C., Khunti, K., Oram, R. A., Knight, B. A., Hattersley, A. T., Jones, A. G., et al. (2016) · British Journal of General Practice · doi:10.3399/bjgp16x684961 · Cited by 87
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial
Leiter, L. A., Teoh, H., Braunwald, E., Mosenzon, O., Cahn, A., Kumar, K. M. P., Smahelova, A., Hirshberg, B., Stahre, C., Frederich, R., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2868 · Cited by 87
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
Giugliano, D., Sportiello, L., Capuano, A., Maiorino, M., Rossi, F., & Esposito, K. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s37647 · Cited by 86
Furler, J., O’Neal, D., Speight, J., Manski-Nankervis, J.-A., Gorelik, A., Holmes-Truscott, E., Ginnivan, L., Young, D., Best, J., dean, et al. (2017) · BMJ · doi:10.1136/bmj.j783 · Cited by 78
Factors associated with weight gain in people with type 2 diabetes starting on insulin
Balkau, B., Home, P. D., Vincent, M., Marre, M., & Freemantle, N. (2014) · Diabetes Care · doi:10.2337/dc13-3010 · Cited by 77
McCoy, R. G., Van Houten, H. K., Ziegenfuss, J. Y., Shah, N. D., Wermers, R. A., & Smith, S. A. (2013) · Endocrine Practice · doi:10.4158/ep12382.or · Cited by 76
Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
Consoli, A., & Formoso, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12101 · Cited by 76
“Pioglitazone, therefore, is the only thiazolidinedione still significantly adopted and is the only molecule of this class still listed in the American Diabetes Association (ADA)-European Association for the Study of Diabetes (EASD) 2012 Position Statement on T2DM treatment [7].”
BackgroundSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
“Chronic hyperglycaemia, frequently combined with other cardiovascular risk factors of the T2D phenotype, is associated with micro- and macrovascular complications, increased mortality and decreased quality of life in many observational studies [3].”
BackgroundImprialos, K. P., Sarafidis, P. A., & Karagiannis, A. I. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000719 · Cited by 71
Khunti, K., Alsifri, S., Aronson, R., Cigrovski Berković, M., Enters-Weijnen, C., Forsén, T., Galstyan, G., Geelhoed-Duijvestijn, P., Goldfracht, M., Gydesen, H., et al. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.05.004 · Cited by 71
Collier, A., Ghosh, S., Hair, M., & Waugh, N. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.09.004 · Cited by 65
Russell-Jones, D., Gall, M.-A., Niemeyer, M., Diamant, M., & Del Prato, S. (2015) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.06.005 · Cited by 66
Self-citationGrimm, M., Han, J., Weaver, C., Griffin, P., Schulteis, C. T., Dong, H., & Malloy, J. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2660 · Cited by 63
Hood, R. C., Arakaki, R. F., Wysham, C., Li, Y. G., Settles, J. A., & Jackson, J. A. (2015) · Endocrine Practice · doi:10.4158/ep15612.or · Cited by 61
Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice
Tajima, K., Nakamura, A., Shirakawa, J., Togashi, Y., Orime, K., Sato, K., Inoue, H., Kaji, M., Sakamoto, E., Ito, Y., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2013 · Cited by 59
“Metformin, a biguanide, remains the most widely used first-line drug for the treatment of type 2 diabetes (16); the drug exerts its effect predominantly by reducing hepatic glucose production (2).”
BackgroundMechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes
Horowitz, M., Rayner, C. K., & Jones, K. L. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0009-4 · Cited by 58
Naik, A. D., Hundt, N. E., Vaughan, E. M., Petersen, N. J., Zeno, D., Kunik, M. E., & Cully, J. A. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.8634 · Cited by 57
Rosal, M. C., Heyden, R., Mejilla, R., Capelson, R., Chalmers, K. A., Rizzo DePaoli, M., Veerappa, C., & Wiecha, J. M. (2014) · JMIR Research Protocols · doi:10.2196/resprot.3412 · Cited by 56
D'Alessio, D., Häring, H. ‐., Charbonnel, B., de Pablos‐Velasco, P., Candelas, C., Dain, M. ‐., Vincent, M., Pilorget, V., Yki‐Järvinen, H., & on behalf of the EAGLE Investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12406 · Cited by 56
“This is compatible with a mechanism of action of basal insulin to control hepatic glucose production overnight and in the intermeal intervals [2,21].”
MethodGu, D.-T., Tung, T.-H., Jiesisibieke, Z. L., Chien, C.-W., & Liu, W.-Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.790901 · Cited by 54
Pencek, R., Blickensderfer, A., Li, Y., Brunell, S. C., & Anderson, P. W. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2567 · Cited by 52
Bruderer, S. G., Bodmer, M., Jick, S. S., Bader, G., Schlienger, R. G., & Meier, C. R. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12282 · Cited by 53
“by fast neurological recovery after glucose administration [1,5,15,16].”
BackgroundChen, Y.-Y., Lin, Y.-J., Chong, E., Chen, P.-C., Chao, T.-F., Chen, S.-A., & Chien, K.-L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123116 · Cited by 56
Cersosimo, E., Johnson, E. L., Chovanes, C., & Skolnik, N. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13108 · Cited by 52
Jude, E. B., Malecki, M. T., Gomez Huelgas, R., Prazny, M., Snoek, F., Tankova, T., Giugliano, D., & Khunti, K. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01222-2 · Cited by 52
Franek, E., Haluzík, M., Canecki Varžić, S., Sargin, M., Macura, S., Zacho, J., & Christiansen, J. S. (2016) · Diabetic Medicine · doi:10.1111/dme.12982 · Cited by 51
Metadata
- Authors
- Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R.
- Affiliations
- Yale New Haven Hospital (US)
- Park Nicollet Clinic (US)
- University of North Carolina at Chapel Hill (US)
- Diabetes Center/Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands; the
- University of Pisa (IT)
- Diabeteszentrum Bad Lauterberg (DE)
- University of Southern California (US)
- Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece; the
- Thomas Jefferson University (US)
- Churchill Hospital (GB)
- Corresponding author
- Inzucchi, Silvio E.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-05-11
- Volume
- 35
- Issue
- 6
- Pages
- 1364-1379
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3357214
- OpenAlex
- W2172193326
- Cited by
- 3,207
- References
- 141
- Citations by year
- 2026: 18 · 2025: 54 · 2024: 72 · 2023: 95 · 2022: 95 · 2021: 119 · 2020: 132 · 2019: 147 · 2018: 218 · 2017: 274 · 2016: 349 · 2015: 477 · 2014: 588 · 2013: 441 · 2012: 124
- FWCI
- 415.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Yale University
- University of Southern California
- University of Miami
- Wayne State University
- Georgetown University
- Case Western Reserve University
- School of Medicine, Case Western Reserve University
- MedStar Health Research Institute
- National Institute for Health and Care Research (NF-SI-0508-10272)
- University of Sydney
- University of Melbourne
- University of Toronto
- European Association for the Study of Diabetes
- Université de Nantes
- University of Ioannina
- University of Illinois at Urbana-Champaign
- School of Medicine, University of Kansas
- Health Science Center, University of Tennessee
- Leonard M. Miller School of Medicine
- Leonard M. Miller School of Medicine, University of Miami
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- hyperglycemia management, type 2 diabetes, glucose-lowering agents, patient-centered care, treatment selection
- MeSH terms
- Age Factors, Algorithms, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Europe, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Kidney Diseases, Liver Diseases, Male, Risk Factors, United States, Patient-Centered Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.